Half Year 2026 CVS Group PLC Earnings Call Transcript
Key Points
- CVS Group PLC (FRA:4C9) successfully transitioned from AIM to the Main Market, which is expected to improve liquidity and access to a more diverse pool of capital.
- The company reported a 5.8% increase in revenue for the first half of 2026, with growth across all divisions.
- Adjusted EBITDA increased by 3.9% to GBP67.7 million, indicating strong financial performance.
- The company's expansion in Australia is progressing well, with acquisitions contributing to 10% of group revenue and 15% of group EBITDA.
- CVS Group PLC (FRA:4C9) maintained a strong balance sheet with leverage at 1.41 times, providing capacity for further expansion and acquisitions.
- The adjusted EBITDA margin decreased by 0.3 percentage points to 19%, impacted by wage inflation and increased national insurance contributions.
- The online retail business only broke even in the first half due to cost of living pressures and price elasticity testing.
- The company faces ongoing challenges from the CMA investigation, with some proposed remedies, such as a price cap on prescription fees, being contested.
- Market conditions in the U.K. remain softer, with lower visit numbers in small animal practices affecting growth.
- Net bank borrowings increased by GBP28.8 million, raising concerns about rising debt levels despite strong cash generation.
Welcome to this presentation of CVS Group's interim results for the six-month period to December 2025. I'm Richard Fairman, CEO. And later, you will also hear from Robin Alfonso, our Chief Financial Officer; and Paul Higgs, our Chief Veterinary Officer.
Our purpose at CVS is to give the best possible care to as many animals as possible, and I'm pleased to report on continued progress in the period. We completed our step-up from AIM to the Main Market on the 29th of January 2026, and we hope this will bring benefits from improved liquidity, access to a more diverse pool of capital, index inclusion from March and an increase in our profile as a company. We have launched our new consumer-facing UK companion animal joint brand under CVS Vets, and you will see this reflected in this presentation.
Now this reflects the care, value and service, which we are renowned for as a trusted partner for our clients. Our presence in Australia is growing with three acquisitions completed in the period and a further two practice
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
